LEO Pharma recieves scientific approval of Enstilar® for the treatment of psoriasis in EU
The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Dermatology Patient care calcipotriol/betamethasone dipropionate enstilar fixed combination topical foam Latest News psoriasis vulgaris Source Type: news
More News: Dermatology | Drugs & Pharmacology | Marketing | Pharmaceuticals | Psoriasis | Skin | Taclonex